SAREPTA THERAPEUTICS INC (SRPT) Stock Analyst Ratings
NASDAQ:SRPT • US8036071004
16.76 USD
-0.69 (-3.95%)
At close: Feb 27, 2026
16.71 USD
-0.05 (-0.3%)
After Hours: 2/27/2026, 8:00:00 PM
ChartMill assigns a Buy % Consensus number of 67% to SRPT. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 30.93. This target is 84.52% above the current price.
- SRPT was analyzed by 33 analysts. The buy percentage consensus is at 67. So analysts seem to be have mildly positive about SRPT.
- In the previous month the buy percentage consensus was at a similar level.
- SRPT was analyzed by 33 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-27 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-27 | HC Wainwright & Co. | Reiterate | Sell -> Sell |
| 2026-01-23 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-01-14 | HC Wainwright & Co. | Reiterate | Sell -> Sell |
| 2025-12-09 | Wedbush | Initiate | Outperform |
| 2025-11-05 | Mizuho | Upgrade | Neutral -> Outperform |
| 2025-11-05 | Guggenheim | Maintains | Buy -> Buy |
| 2025-11-05 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-04 | Baird | Maintains | Neutral -> Neutral |
| 2025-10-30 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-09-22 | BMO Capital | Upgrade | Market Perform -> Outperform |
| 2025-09-15 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-09-09 | Leerink Partners | Maintains | Market Perform -> Market Perform |
| 2025-08-25 | HC Wainwright & Co. | Reiterate | Sell -> Sell |
| 2025-08-21 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-08-20 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-08-15 | Deutsche Bank | Maintains | Sell -> Sell |
| 2025-08-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-07 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-07-30 | Barclays | Upgrade | Underweight -> Equal-Weight |
| 2025-07-29 | Bernstein | Initiate | Market Perform |
| 2025-07-29 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2025-07-29 | Needham | Reiterate | Underperform -> Underperform |
| 2025-07-29 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2025-07-29 | Barclays | Upgrade | Underweight -> Equal-Weight |
| 2025-07-29 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2025-07-29 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-29 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-07-28 | Needham | Reiterate | Underperform -> Underperform |
SAREPTA THERAPEUTICS INC / SRPT FAQ
What is the average price target for SAREPTA THERAPEUTICS INC (SRPT) stock?
33 analysts have analysed SRPT and the average price target is 30.93 USD. This implies a price increase of 84.52% is expected in the next year compared to the current price of 16.76.
How do analysts rate SAREPTA THERAPEUTICS INC (SRPT)?
The consensus rating for SAREPTA THERAPEUTICS INC (SRPT) is 67.2727 / 100 . This indicates that analysts generally have a neutral outlook on the stock.